{"id":"carbamazepine-er-equetro","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Dizziness"},{"rate":"20-30","effect":"Ataxia"},{"rate":"20-30","effect":"Somnolence"},{"rate":"25-35","effect":"Diplopia"},{"rate":"15-25","effect":"Blurred vision"},{"rate":"15-25","effect":"Nausea"},{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"1-5","effect":"Hyponatremia"},{"rate":"<1","effect":"Agranulocytosis"}]},"_chembl":{"chemblId":"CHEMBL108","moleculeType":"Small molecule","molecularWeight":"236.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbamazepine acts primarily as a sodium channel blocker, which decreases the influx of sodium ions into neurons and stabilizes the inactive state of the channel. This reduces the frequency of action potentials and neuronal excitability. The extended-release formulation (Equetro) provides sustained drug levels to maintain therapeutic effects with reduced dosing frequency.","oneSentence":"Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:08.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar I disorder, acute mania and mixed episodes"},{"name":"Epilepsy (seizure disorders)"},{"name":"Trigeminal neuralgia"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT00181870","phase":"PHASE4","title":"Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-07","conditions":"Bipolar Disorder, Mania","enrollment":33},{"nctId":"NCT00203567","phase":"PHASE4","title":"Carbamazepine Extended-Release for the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Tuscaloosa Research & Education Advancement Corporation","startDate":"2005-08","conditions":"Bipolar Depression","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"carbamazepine ER (Equetro)","genericName":"carbamazepine ER (Equetro)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels. Used for Bipolar I disorder, acute mania and mixed episodes, Epilepsy (seizure disorders), Trigeminal neuralgia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}